Barbara Staehelin just increased her shareholding as well so would seem a definite show of confidence in company and worth. Wonder how many more purchases we may see and if purchases cease if that will then indicate imminent good news?
Ian Ross just purchased another 100k shares,now has 0.7% holding. I guess the view internally is very good re cash burn and prospects.Directors steadily making share purchases.I can only assume that they are very confident of something happening in next 12 months and as they have the experience of the industry and these situations I hope they confidence is well founded.
as a seasoned investor possibly advantageous from a tax point of view to sell now.No immediate prospect of deals so sell now,record loss against other gains to reduce tax liability then rebuy when things look better but price still low.Just one possible scenario.Also,why tie up cash with little short term possibility of recovery when there may be other opportunities available to recoup some of the losses. As a LTH I will just stick in there....had more or less written shares off so any good news can only be a gain. I still firmly believe in the "product" but being able to sell that to the market is a different story unfortunately.At least we now have experienced management who also invested so have a big interest in getting best value for the technology.
You also have to ask who holds the shares & would they be prepared to sell for peanuts? I think the majority of shareholders have lost so much money they would rather lose the "peanuts" they have but with a chance of recouping at least a decent proportion of their losses rather than seeing the company bought outright for next to nothing! Why would we worry about selling when we have already lost so much...may as well stay until the end as we have as good as nothing now in value terms! I would not sell,I still have faith even if it seems misplaced at times.
Surprised2...from Johns Hopkins "Each brain hemisphere (parts of the cerebrum) has four sections, called lobes: frontal, parietal, temporal and occipital. Each lobe controls specific functions.". So looks like there are 4 as stated on the Reneuron RNS.
Re any steady share price increase I think that is some way off.We need some really good news flow and until that time all we will see is price inreases followed by sell off from "speculators" and price drops! A good deal from Fosun and other deals for decent values/income would hopefully see the price start a nice upward trajectory but I am not concinced we will see that any in the near future unfortunately.
I think current "closed period" may relate to ongoing negotiations with Fosun (previously raised in this chat facility).As I understand it the directors cannot purchase shares whilst price sensitive issues prevail as they are deemed to have access to price sensitive/inside information.As such the directors will be able to purchase once the details of any deal are released to the markets.Likewise there are restrictions relating to compilation and release of financial results. Regulations to prevent insider dealing I think.
I think this is a good move and agree it should be seen as a positive.OH always presented a positive view of the company and its research but what is now needed is honest reporting of updates as and when data is available (in my view lacking with RP). The experience of the new directors will hopefully see the company regain trust of investors and help us to achieve goals in both development of exosomes and the related value for shareholders (especially those of us who are long term holders who have seen our faith in the company extremely poorly rewarded!).
Hi Allenby.My comment on Obotritia was not what I thought just observation.A company with limited but rich investors has less pressure to sell normally compared to an investment fund with thousands of investors who are already fed up with losing money from Woodford investments (Schroeder took on his fund) and need access to their "savings". If Schroeders are hit with a high withdrawal rate they would be a forced seller. Obotritia would make a judgement call based on what they feel is best in short/medium/long term therefore not pressure but well thought out and planned.It could be they retain some interest,maybe they are bailing completely,only they know and time will tell.Possibly they are exiting now to make best use of loss for tax purposes and will re-enter later.Who knows? Unlike the Schroeder hit when they sold recently we are not currently seeing price drops,fingers crosed the price will hold up.I wonder if they have a specific buyer(s) for the shares they are selling?
Thank you SAJY
Have been having a further look after some of the comments.There is also a "quiet period" (possibly more a US concept but presumably same rules apply elsewhere) where you cannot trade if you have price sensitive information pre market announcements. The suggestion that it may have something to do with Fosun negotiations seems logical as this could be price sensitive info so anyone involved or who had knowledge of developments should not be able to profit prior to official notices..This could explain the general lack of BOD share purchases since 2019 (apart from the rights issue and Barbara Staehelin) as there were so many negotiations ongoing re licences and collaborations. SAJY possibly correct concept but maybe not correct term?Perhaps we will have to wait for Fosun deal to be finalised and announced before BOD can buy/sell.
Re the Fosun staffing,I think it was that Fosun would be using ReNeuron staff to assist with progressing their work so would pay their salaries but I do not think OH mentioned if they remain UK based or transfer to China.I would see it as general expenses so no need for an RNS but should be reflected in accounts (reduced salary outgoings or special payments).Good though as it means another cost saving for ReNeuron.
SAJY stated on 26/01/22 that company was in closed period therefore reason for no buys.I assumed that was correct and repeated but looking at defintions/rules I do not think they are in a closed period as this is related to relase of interim or full results and I cannot see we are expecting anything now until FY Results in July. Can anyone confirm?
Re Obotritia,may just be "adjusting" their interest.I would be more concerned over Shroeder selling up.Obotritia seems to be more of a private holding so less pressure to sell,more desire to hold and recoup.As yet not heard about any other major investor looking to flee.
Re Barbara Staehelin,we wait to see what the BOD will do re share purchases when the "closed period" ends.
Thanks for providing the link Phil.Good presentation and explained more about the value/problems/decisions re RP treatment. Seems there is still potential and I can understand cessation due to costs of finding right target group(s).Also noted that the original group has "declined" so less data to assess efficacy over time but even then the results were encouraging.However,I also noted the comment re effects probably "stabilising" not "regenerative" which to me would put different complexion on product unless a company sees benefit in delivery method with another potential treatment.
Exosome news re collaborations is upbeat and I liked the thoughts that company is really undervalued based on where they are and what they have achieved to date.Cagey but expected answers to whether directors would buy shares at this price,but from what OH said-IMHO I would say their view has to be positive to buying.
Fosun news was good.Slow start but now ReNeuron really happy they have started to invest more money to make progress. Hopefully news flow from Fosun will be forthcoming over the next months (and fingers crossed of a positive nature!). I also liked the comments from OH regarding competitors in that if they have good results/news from trials it can boost ReNeuron's value as well as it would be proving the value of exosomes.
We can only wait and see where the price goes as there is no logic at present.But if 1 company has major breakthrough in terms of a product then possibly that will be the catalyst to properly value the market and ReNeuron in particular.
I think the main problem to overcome is trust in certain member(s) of the board.How can you strongly infer that you have a product that could go to market (RP @ 1mil cell dose) if the increased dosage does not work then many months later pull the plug stating problems with administering treatment,1 mil cell dose not stable/efficient and we need someone else to take this forward.I,like many others,were topping up our shares as the price dropped towards £1 or below in the belief we were on a firm footing with a potential product in the pipeline,but the company said NOTHING re problems they were already experiencing (first patients at increased dosage were treated first half of 2021,no comments even when the infection halted treatment). I strongly believe that "negative" information should have been divulged a lot earlier as it is "price sensitive" and many were expecting remuneration from RP to support exosome project progress.
I fully support the decision to concentrate on exosome development but withholding key developments re. RP to me is inexcusable as it has destroyed trust and the price.Will any major investor now have full faith in what is being said by the BOD?
Once allowed to purchase shares again it will be very interesting to see if BOD buy in at current price levels or even what their current holdings are (the figures on here are out of date as they do not even reflect additional shares taken up in the last fund raising I believe).
when the share price has dropped 80% from its 52 week high this is hardly a bounce....more like an anomaly! Besides which,the price rises a bit and loads of people sell so it is never sustained unfortuantely.
We can only hope we see a change in attitude from the company now re. notifying markets of important issues. How is it we only had updates re 1st cohorts and troubles with surgical applications when they were pulling the RP project?Must have known this for some months.Very poor. Hopefully the news (bad as it was) signals a mindset change by the new board members,but damage has been done to trust and who knows if/when that will be repaired. I always believed the value lay in exosomes with RP possibly being the means to fund over the short term so I totally agree this has been oversold. However, I believe Schroeders are still struggling with their Woodford legacy (will more clients will now withdraw investments?No new money coming in to fund?) so may decide to take the hit and cash in. We can only hope the other major investors stay put and hope to recoup losses/make gains at some point.A mess. I expect further drops in SP as people sell up & cut losses so would not consider buying even at this low price.
Re change of personnel at the top.....I think THE top person should look hard at all the positive vibes being sent while the RP indications were the opposite.Everywhere I checked they just stated the 1st cohort was a 12 month "safety" assessment. Now it seems it has other implications (possibly still something to gain from it if we can find someone to buy a license and spend money identifying who may benefit from it/further develop treatment).
However,decision to concentrate on exosomes is positive especially as we seem to be in a good development position at present and cannot afford to fall behind.It is going to be a fast developing market and we need to stay out front.
Also good that further licensing deals are ongoing with Fosun.May not be much but at least they are still on-board. I just worry that the latest news weakens our negotiating position in general.
I think I will "bury" these shares for a few years and write it off as "experience".
Totally agree. Reneuron have cash and have also shown good financial management so I cannot see a placing any time soon. With the RP treatment I would expect a major pharma to come on board with funding to get the treatment to market if required (if I remember correctly the current treatment they have for RP passes relevant safety criteria to allow it for use if they decided to market it sooner rather than later).
I have no idea why the price is dropping when all news seems to be positive at present.Could just be a mix of other news (Omicron,Theranos scandal,speculators getting cold feet re. lack of news on deals etc). We should have updates within weeks on latest RP trials at which point the brokers will issue a revised target price.That will be interesting as more positive news has emerged since last update other than the RP treatment-I would expect target price to increase.
I have topped up a little again today as I feel the price is far too low,but this will be it now.Hopefully the faith of all the LTI's will be rewarded sooner rather than later. 2022 looks to be a pivotal year for Reneuron as their products are being positively reviewed by their peers,and hopefully a really positive one!
Grizzlyb...totally agree that this stock is grossly undervalued!
Dipped in to buy again today.All reports are very promising yet market treating this share negatively. Collaborations/ licences are bound to materialise sooner rather than later and I can only see the positive news putting Reneuron in a stronger negotiating position. I have always felt they have absolute confidence in the science and their product line so will ensure they get very best value for shareholders.Would be nice to know where the price will be in 12 months,but then that would spoil the "fun" of holding a share that seems to drop every time we receive really positive news!!!
totally agree Stateside,cash runway is misleading.According to Edison's latest research note Reneuron had cash as at 03/2021 to last at least 12 months but they added they felt that could be extended to last until Q4 FY23. Amazing that Tesla is worth billions yet never has or probably will ever produce a profit,Reneuron has what looks like a glowing,profitable future ahead yet cannot realise a "true value"!Must be annoying for the directors as well as they have a target to generate value for shareholders as part of their share options yet the ahare price cannot reach "escape velocity".Hopefully soon we will move to a more realistic market index.
Re costs for further trials after yesterday's news OH stated that the pharma we are collaborating with would pay for those expenses so Reneuron really only has to concentrate on costs for RP at present in addition to day-to-day expenses.
Just shows this share is listed in totally wrong market place!Every time we have positive news share drops,really positive it flies only only to crash again and with latest brilliant news it is doing another fly/crash! Need to get off the AIM. If the company was valued at £3+ / share (Edison) before yesterdays news I would expect that valuation to increase now even if only by a small amount yet here we are with loads of selling and the price heading downwards. Really is unbelievable.